Making Sense in Antisense: Therapeutic Potential of Noncoding RNAs in Diabetes-Induced Vascular Dysfunction

Figure 3

miRNAs involved in vascular pathophysiology. ECs: endothelial cells; VSMCs: vascular smooth muscle cells; SIRT1: silent mating type information regulation 2 homolog; ITGA5: integrin subunit α5; JAK1: Janus kinase 1; KLF: Krüppel-like factor; ELK1: ETS domain-containing protein Elk1; PPARα: peroxisome proliferator-activated receptor α; SPROUTY2: sprouty protein 2; SEMA6A: semaphorin-6A; SPRED1: sprouty-related, EVH1 domain-containing protein 1; GATA2: GATA-binding protein 2; PAK4: p21 protein-activated kinase 4; PI3KR2: phosphatidylinositide 3-kinase regulatory subunit 2; VCAM1: vascular cell adhesion molecule 1; HIF: hypoxia-inducible factor 1; ZEB1: Zinc Finger E-Box Binding Homeobox 1; PTEN: phosphatase and tensin homolog; PDCD4: programmed cell death 4; CAMK2D: calcium/calmodulin-dependent protein kinase II delta; PDGF: platelet-derived growth factor; ACE: angiotensin-converting enzyme; KIT: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CDKN1B: cyclin-dependent kinase inhibitor 1B.